American generic company, Amneal Pharmaceuticas has announced the forthcoming launch of Tobramycin AN inhalation system, the first generic equivalent of Tobi in Australia.
Amneal Australia gm Gavin Upiter said, "This highly complex antibacterial drug is the first inhalation solution formulation from Amneal Pharmaceuticals and is its third first-to-market generic product launched in Australia in the last 12 months."
The key patient group is those living with cystic fibrosis, creating a revenue potential of some $3,000 per pharmacy on average.
Tobramycin AN was PBS-listed on 01 Aug and is now available to order at a considerable discount through all major wholesalers.
Amneal Australia said it has plans to register 50 molecules in the Australian market in the next three years.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Sep 16